Processa Pharmaceuticals stock analysis
Want to see PCSA full AI Analyst Report?
Processa Pharmaceuticals (PCSA) Stock Price & Analysis
PCSA Stock Chart & Stats
- Day’s Range
- $1.86 - $1.95
- 52-Week Range
- $1.04 - $8.88
- Previous Close
- $1.84
- Volume
- N/A
- Average Volume (3M)
- 139.16K
- Market Cap
- $5.40M
- Enterprise Value
- $5.09M
- Total Cash (Recent Filing)
- $196.32K
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.33
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Immunology Pipeline Expansion
FDA clearance and multiple planned Phase 2 programs broaden Processa beyond a single development opportunity. Progress across chronic urticaria, food allergy and multiple sclerosis could diversify clinical catalysts and create a more durable platform if studies demonstrate efficacy and safety.
Significant Financing
The approximately $200 million private placement provides substantial financial support for clinical development and pipeline execution relative to the company’s prior development-stage resources. This can extend operating capacity and reduce immediate dependence on repeated fundraising while programs advance.
Experienced Leadership Build-out
Adding experienced leaders across operations, research, development and business functions strengthens the organizational capabilities needed to manage a broader clinical portfolio. The team’s stated experience may improve execution discipline as Processa advances VT-7208 and integrates its expanded strategy.
Bears Say
No Demonstrated Revenue Base
Processa remains pre-commercial, with no reported revenue to offset research and development spending and recurring losses of about $13.4 million TTM. Until a program reaches commercialization, the company has no demonstrated operating revenue base to support sustained self-funded growth.
Persistent Cash Burn
Sustained negative operating and free cash flow shows that clinical progress currently requires continued funding rather than internally generated cash. Ongoing burn can constrain strategic flexibility and increase reliance on external capital as multiple programs move through development.
Substantial Dilution Risk
The expected as-converted share count is far above the stated common shares outstanding, creating substantial dilution potential for existing holders. This enlarged equity base can reduce each holder’s proportional participation in future value even if the clinical strategy progresses.
Processa Pharmaceuticals News
Processa Pharmaceuticals names Gregory Flesher COO, adds three executives
Processa Pharmaceuticals (PCSA) announced key leadership appointments to support the company’s next phase of growth: Gregory Flesher, COO; Craig Coburn, executive VP, head of research; Ashley Hall, executive VP, development;
Processa Pharmaceuticals acquires Vidya Therapeutics in stock-for-stock deal
Processa Pharmaceuticals (PCSA) announced it has acquired Vidya Therapeutics. Concurrent with the acquisition, Processa entered into a definitive agreement for a private placement financing expected to result in gross proceeds
PCSA FAQ
What was Processa Pharmaceuticals’s price range in the past 12 months?
What is Processa Pharmaceuticals’s market cap?
When is Processa Pharmaceuticals’s upcoming earnings report date?
How were Processa Pharmaceuticals’s earnings last quarter?
Is Processa Pharmaceuticals overvalued?
Does Processa Pharmaceuticals pay dividends?
What is Processa Pharmaceuticals’s EPS estimate?
How many shares outstanding does Processa Pharmaceuticals have?
What happened to Processa Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Processa Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- George K. Ng
- Employees
- 12
- Website
- www.processapharmaceuticals.com
- Address
- 601 21st Street, Vero Beach, FL, 32960, US
Processa Pharmaceuticals (PCSA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 8 | 0 | 4 |
